share_log

Cantor Fitzgerald Reiterates Overweight on Structure Therapeutics, Maintains $65 Price Target

Cantor Fitzgerald Reiterates Overweight on Structure Therapeutics, Maintains $65 Price Target

康达信(Cantor Fitzgerald)重申对Structure Therapeutics的股票评级为强于大盘(Overweight),维持其目标股价为65美元。
Benzinga ·  08/15 08:21  · 评级/大行评级

Cantor Fitzgerald analyst Prakhar Agrawal reiterates Structure Therapeutics (NASDAQ:GPCR) with a Overweight and maintains $65 price target.

Cantor Fitzgerald分析师Prakhar Agrawal重申Structure Therapeutics(纳斯达克:GPCR)的股票评级为超配,维持65美元的目标价格。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发